Possibly another shot on goal for this company with Kevetrin:
"We show that p53 inhibits replication of infectious SARS-CoV as well as of replicons and human coronavirus NL63. Hence, human coronaviruses antagonize the viral inhibitor p53 via stabilizing RCHY1 and promoting RCHY1-mediated p53 degradation." https://www.pnas.org/content/113/35/E5192